About

James Gilligan, PhD, Founder & Chief Scientific Officer, Tarsa Therapeutics, has held positions of increasing responsibility for nearly 30 years at Unigene Laboratories, where he led the development of the oral calcitonin product now licensed to Tarsa. He served as Vice-President of Product Development at Unigene, where he was project leader for the oral and nasal calcitonin programs, as well as the oral parathyroid hormone and site-directed bone growth programs. Dr Gilligan was responsible for leading the clinical programs and successful US and European regulatory registrations for the nasal calcitonin product Fortical® Nasal Spray and the injectable calcitonin product Forcaltonin® Injection. Dr Gilligan holds a PhD in pharmacology toxicology from the University of Connecticut and a Master’s degree in international business from the Stillman School of Business at Seton Hall University.